findmyKOL
Clinical trialNCT05495243CompletedPhase 2Interventional

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

SponsorRenovion, Inc.Enrollment40Non-cystic Fibrosis Bronchiectasis
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, Phase 2a, double-blind, placebo-controlled study to evaluate the safety and efficacy of ARINA-1 compared to placebo (isotonic saline, 0.9%) in participants with NCFBE. Study participants will receive either study treatment or placebo twice daily for 28 days. Efficacy endpoints will include quality of life, sputum rheological markers, and blood inflammatory markers. Quality of life will be measured using the following tools: Quality of Life-Bronchiectasis (QOL-B) questionnaire, St. George's Respiratory Questionnaire (SGRQ), Chronic Airways Assessment Test (CAAT), and a daily clinical global impression questionnaire.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Alabama - Birmingham

    Birmingham, Alabama, United States

  • National Jewish Hospital

    Denver, Colorado, United States

  • Georgetown University

    Washington D.C., District of Columbia, United States

  • Louisiana State University

    New Orleans, Louisiana, United States

  • Johns Hopkins

    Baltimore, Maryland, United States

  • Southeastern Research Center

    Winston-Salem, North Carolina, United States

  • Oregon Health and Science University

    Portland, Oregon, United States

  • Jefferson Hospital

    Philadelphia, Pennsylvania, United States

  • Medical University of South Carolina

    Charleston, South Carolina, United States

  • University of Texas - Tyler

    Tyler, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ARINA-1Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
3 Oct 2022
Primary completion
1 Feb 2024
Completion
1 Feb 2024
Last update posted
23 Jul 2025
Registered enrollment
40
Registry id
NCT05495243
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.